RACHELLE DOODY to Female
This is a "connection" page, showing publications RACHELLE DOODY has written about Female.
Connection Strength
1.129
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29.
Score: 0.038
-
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
Score: 0.038
-
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact. J Prev Alzheimers Dis. 2024; 11(3):537-548.
Score: 0.035
-
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
Score: 0.035
-
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
Score: 0.033
-
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab. J Prev Alzheimers Dis. 2021; 8(1):3-6.
Score: 0.029
-
Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. J Prev Alzheimers Dis. 2021; 8(2):151-160.
Score: 0.029
-
Longitudinal Sensitivity of Alzheimer's Disease Severity Staging. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec; 35:1533317520918719.
Score: 0.027
-
Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
Score: 0.027
-
Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
Score: 0.022
-
Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease. PLoS One. 2016; 11(8):e0160671.
Score: 0.021
-
Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. J Clin Exp Neuropsychol. 2016; 38(5):516-26.
Score: 0.020
-
How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? Clin Neuropsychol. 2015; 29(7):1002-9.
Score: 0.020
-
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr. 2016 12; 21(6):450-459.
Score: 0.020
-
Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. Psychol Assess. 2015 Dec; 27(4):1234-40.
Score: 0.019
-
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 04 10; 370(15):1460.
Score: 0.018
-
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21.
Score: 0.018
-
Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 10 24; 369(17):1661.
Score: 0.018
-
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50.
Score: 0.017
-
Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
Score: 0.017
-
Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 34(5-6):360-72.
Score: 0.016
-
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
Score: 0.016
-
Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012 Jul; 8(4):288-94.
Score: 0.016
-
Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. Dement Geriatr Cogn Disord. 2011; 32(5):362-6.
Score: 0.016
-
Greater precision when measuring dementia severity: establishing item parameters for the Clinical Dementia Rating Scale. Dement Geriatr Cogn Disord. 2012; 34(2):128-34.
Score: 0.015
-
Dementia staging across three different methods. Dement Geriatr Cogn Disord. 2011; 31(5):328-33.
Score: 0.015
-
Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample. Dement Geriatr Cogn Disord. 2010; 30(6):486-91.
Score: 0.014
-
Identifying amnestic mild cognitive impairment in primary care: a feasibility study. Clin Drug Investig. 2011; 31(7):483-91.
Score: 0.014
-
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
Score: 0.013
-
How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009; 28(1):63-9.
Score: 0.013
-
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement. 2009 Mar; 5(2):122-4.
Score: 0.013
-
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
Score: 0.013
-
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15.
Score: 0.012
-
Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
Score: 0.012
-
Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007; 24(6):476-82.
Score: 0.012
-
Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007; 24(5):375-9.
Score: 0.011
-
Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007 Jan; 22(1):99-107.
Score: 0.011
-
Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005; 20(2-3):198-208.
Score: 0.010
-
Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
Score: 0.010
-
Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005 Mar; 62(3):454-9.
Score: 0.010
-
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
Score: 0.009
-
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
Score: 0.009
-
The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls. Alzheimer Dis Assoc Disord. 2004 Oct-Dec; 18(4):236-40.
Score: 0.009
-
Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005; 24(1-2):42-50.
Score: 0.009
-
Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 18(2):227-32.
Score: 0.009
-
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat Med. 2024 Apr; 30(4):1096-1103.
Score: 0.009
-
WAIS-R factor structure in Alzheimer's disease patients: a comparison of alternative models and an assessment of their generalizability. Psychol Aging. 2003 Dec; 18(4):836-43.
Score: 0.009
-
Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. Arch Clin Neuropsychol. 2003 Jan; 18(1):19-32.
Score: 0.008
-
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
Score: 0.007
-
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021 Jul; 27(7):1187-1196.
Score: 0.007
-
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
Score: 0.007
-
A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):449-54.
Score: 0.007
-
Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. Alzheimer Dis Assoc Disord. 2001 Jan-Mar; 15(1):1-9.
Score: 0.007
-
Chinese Version of the Baylor Profound Mental Status Examination: A Brief Staging Measure for Patients with Severe Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(2):175-180.
Score: 0.007
-
Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000 Nov; 69(5):668-71.
Score: 0.007
-
The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol. 1999 Sep; 56(9):1133-7.
Score: 0.007
-
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A?, tau, immunity and lipid processing. Nat Genet. 2019 03; 51(3):414-430.
Score: 0.006
-
Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Dis Assoc Disord. 1999 Jan; 13(1):53-9.
Score: 0.006
-
Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1998 Dec; 12(4):263-5.
Score: 0.006
-
Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade. J Gerontol B Psychol Sci Soc Sci. 2018 08 14; 73(6):964-973.
Score: 0.006
-
Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. J Int Neuropsychol Soc. 1997 Sep; 3(5):420-7.
Score: 0.006
-
Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997; 9(1):68-74.
Score: 0.005
-
Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data. J Alzheimers Dis. 2017; 58(2):361-371.
Score: 0.005
-
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
Score: 0.005
-
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 09; 16:89.
Score: 0.005
-
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016 07; 28:41-48.
Score: 0.005
-
Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
Score: 0.005
-
Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. J Clin Exp Neuropsychol. 1996 Feb; 18(1):110-21.
Score: 0.005
-
Validation of the Spanish version of the Baylor Profound Mental Status Examination. J Alzheimers Dis. 2016; 49(1):73-8.
Score: 0.005
-
Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry. 1995 Sep; 152(9):1377-9.
Score: 0.005
-
Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimers Dement. 2016 Jan; 12(1):75-84.
Score: 0.005
-
Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(1):54-60.
Score: 0.005
-
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
Score: 0.005
-
Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2014; 41(4):1063-71.
Score: 0.004
-
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
Score: 0.004
-
A reappraisal of localization theory with reference to aphasia. Part 1: Historical considerations. Brain Lang. 1993 Apr; 44(3):296-326.
Score: 0.004
-
A reappraisal of localization theory with reference to aphasia. Part 2: Language theories from outside neurology. Brain Lang. 1993 Apr; 44(3):327-48.
Score: 0.004
-
The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3.
Score: 0.004
-
Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dement Geriatr Cogn Disord. 2014; 37(1-2):45-57.
Score: 0.004
-
Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis. 2013; 33(2):517-23.
Score: 0.004
-
Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. Transl Psychiatry. 2012 Nov 20; 2:e192.
Score: 0.004
-
The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
Score: 0.004
-
Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging. 2013 Mar; 34(3):663-78.
Score: 0.004
-
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
Score: 0.004
-
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092.
Score: 0.004
-
A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(1):55-62.
Score: 0.004
-
Long-term treatment with lithium alleviates memory deficits and reduces amyloid-? production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2011; 24(4):739-49.
Score: 0.004
-
Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
Score: 0.004
-
Spasmodic dysphonia associated with palatal myoclonus. Ear Nose Throat J. 1990 Dec; 69(12):829-32.
Score: 0.004
-
A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010 Sep; 67(9):1077-81.
Score: 0.004
-
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 Mar 23; 74(12):956-64.
Score: 0.003
-
Consequences of aggressive behavior in patients with dementia. J Neuropsychiatry Clin Neurosci. 2010; 22(1):40-7.
Score: 0.003
-
Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
Score: 0.003
-
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
Score: 0.003
-
Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(1):69-75.
Score: 0.003
-
Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008 Aug; 65(8):1091-5.
Score: 0.003
-
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.
Score: 0.003
-
Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res. 2008 Oct; 42(14):1203-12.
Score: 0.003
-
Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
Score: 0.003
-
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
Score: 0.003
-
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38.
Score: 0.003
-
Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
Score: 0.003
-
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
Score: 0.003
-
Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
Score: 0.003
-
Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005; 20(6):338-44.
Score: 0.002
-
Factors affecting deficit awareness in persons with dementia. Dement Geriatr Cogn Disord. 2005; 20(2-3):133-9.
Score: 0.002
-
Accuracy of self-reported depression in persons with dementia. J Am Geriatr Soc. 2005 Mar; 53(3):389-96.
Score: 0.002
-
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
Score: 0.002
-
Dementia Deficits Scale. Rating self-awareness of deficits. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):22-31.
Score: 0.002
-
Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
Score: 0.002
-
Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 03; 348(14):1333-41.
Score: 0.002
-
A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002 Feb 12; 58(3):433-7.
Score: 0.002
-
Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement Geriatr Cogn Disord. 2002; 13(1):8-12.
Score: 0.002
-
Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec; 58(12):1985-92.
Score: 0.002
-
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14; 57(3):481-8.
Score: 0.002
-
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May; 10(3):195-203.
Score: 0.002
-
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15.
Score: 0.002
-
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
Score: 0.001
-
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan; 50(1):136-45.
Score: 0.001
-
Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997 Jul; 49(1):44-50.
Score: 0.001
-
The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1997 Jul; 49(1):70-5.
Score: 0.001
-
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32.
Score: 0.001
-
Establishing the limits of the Mini-Mental State. Examination of 'subtests'. Arch Neurol. 1992 Jan; 49(1):87-92.
Score: 0.001